BI Asset Management Fondsmaeglerselskab A S Trims Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

BI Asset Management Fondsmaeglerselskab A S lowered its stake in Hologic, Inc. (NASDAQ:HOLX) by 6.7% during the 1st quarter, Holdings Channel reports. The institutional investor owned 12,821 shares of the medical equipment provider’s stock after selling 919 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Hologic were worth $1,000,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Massmutual Trust Co. FSB ADV raised its stake in Hologic by 24.7% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock worth $54,000 after acquiring an additional 137 shares during the period. Graypoint LLC raised its position in shares of Hologic by 3.9% during the 1st quarter. Graypoint LLC now owns 3,871 shares of the medical equipment provider’s stock valued at $302,000 after purchasing an additional 147 shares during the period. Arizona State Retirement System raised its position in shares of Hologic by 0.3% during the 4th quarter. Arizona State Retirement System now owns 67,319 shares of the medical equipment provider’s stock valued at $4,810,000 after purchasing an additional 172 shares during the period. Lincoln National Corp lifted its stake in shares of Hologic by 4.0% during the 4th quarter. Lincoln National Corp now owns 4,675 shares of the medical equipment provider’s stock valued at $334,000 after buying an additional 178 shares in the last quarter. Finally, Allworth Financial LP boosted its holdings in Hologic by 39.3% in the 4th quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 179 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Citigroup raised Hologic from a “neutral” rating to a “buy” rating and raised their price target for the company from $80.00 to $95.00 in a report on Wednesday, April 3rd. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. JPMorgan Chase & Co. upped their price target on Hologic from $85.00 to $91.00 and gave the stock an “overweight” rating in a research note on Friday, May 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price objective on shares of Hologic in a report on Friday, May 3rd. Finally, Evercore ISI lowered their target price on shares of Hologic from $78.00 to $76.00 and set an “in-line” rating on the stock in a report on Tuesday, July 2nd. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $85.55.

Hologic Price Performance

HOLX traded up $0.08 during trading hours on Wednesday, hitting $74.83. The company’s stock had a trading volume of 206,443 shares, compared to its average volume of 1,612,429. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $82.45. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52. The business’s 50-day moving average price is $74.00 and its 200-day moving average price is $74.47. The stock has a market cap of $17.46 billion, a price-to-earnings ratio of 38.12, a P/E/G ratio of 2.48 and a beta of 0.99.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.05. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. During the same quarter last year, the firm earned $1.06 EPS. The firm’s revenue for the quarter was down .8% compared to the same quarter last year. Sell-side analysts expect that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.